Overview
Cell-based therapies are being used increasingly to treat many diseases for which no other adequate treatment options are currently available. These therapies contain modified human cells that can regenerate or augment a recipient's dysfunctional cells, tissues or organs. Cells biological characteristics are typically altered ex vivo before administration of the final product to patients.
Every constituent of the supply chain must be seamlessly orchestrated for a cell therapy product to reach every patient. From collection of cells through production into a drug product and reverse logistics back to the patient, this process is very complex but a risk based approach can mitigate potential challenges.
Learning Objectives:
- Understand how product characteristics can influence your approach to managing the Cell Therapy supply chain.
- Understand what might influence the decision to have centralized or localized manufacturing strategies.
- Understand the information that is required to successfully import and export Cell Therapy materials.
Speakers:
Miss Rachel Griffiths
Associate Director, Technical Services, PCI Clinical Services
Rachel joined the company in 2004 and has held leadership roles in Operations and Technical Support. Her current role involves overseeing the installation and validation of new facilities at the company's Bridgend site and the implementation of new technologies and innovations in controlled-temperature packaging, storage and distribution services. With a degree in Microbiology and Virology, Rachel is the Biological Safety Officer for the Bridgend site and also has previous experience as a development scientist, a technical support scientist and a product support specialist.
Dr. Matthew Lakelin
Vice President Scientific Affairs and Business Development, TrakCel
Matthew Lakelin has been working at TrakCel since the company's formation, his role at TrakCel is varied including assisting with product development, business development and he sits on the company's Quality Unit and Scientific Advisory Board. Prior to TrakCel Matthew had a number of roles in the pharmaceutical industry directly related to distribution and management of advanced therapies. He has a PhD in Pharmacology from the Welsh School of Pharmacy.
Mr David Gray (Host)
Deputy Group Editor, Rapid Life Sciences
This webinar will be hosted by David Gray, Deputy Group Editor of Rapid Life Sciences. David's career has seen him provide an authoritative voice for readers in manufacturing, healthcare, life sciences, consumer tech, and lifestyle.
Register Now!
Already registered for this webinar?
Just enter the email address you used to register.
First time here?
Please fill in the registration form below.
